NeoVac appoints Jan H Egberts as chief executive officer
pharmafile | September 17, 2025 | Appointment | Analytical & Laboratory Services, Business Services, Clinical Trial Services, Research and Development | Devices, Lipid Nanoparticle Technology, Neovac, mRNA Therapies
NeoVac, a clinical-stage biopharma based in Abingdon, UK, has appointed Jan H Egberts as chief executive officer.
The company is developing RNA-based therapies using its proprietary lipid nanoparticle (LNP) delivery platform.
Egberts brings more than 25 years of executive leadership experience across the pharma and healthcare investment sectors. Most recently, he was CEO of Veritas Investments, which owns eight medical device and services companies across Europe and holds minority equity stakes in ten privately held healthcare businesses. Earlier in his career, he served as CEO of OctoPlus prior to its acquisition by Dr Reddy’s, and has chaired companies including ViroClinics, Photocure ASA, and Nordic Nanovector ASA.
“As one of the earliest investors in the company I have a long-held belief in NeoVac’s vision for RNA delivery through NeoVav’s proprietary LNP platform featuring clinically validated improved safety,” Egberts commented. “I look forward to working closely with our team to accelerate development programs and expand global access to our technology.”
NeoVac’s LNP platform is designed to support applications across inflammation, oncology, gene editing and infectious diseases. According to the company, the technology enables tuneable immune activation, tissue-specific targeting, high RNA payload capacity and enhanced safety through the use of biodegradable materials.
In addition, NeoVac has developed thermostable formulations that remain stable at room temperature, which could provide significant advantages for vaccines developed with the platform.
Charlie Blackie-Kelly
17/9/25
